Study of Pfizer's Revatio in Sickle cell disease halted over safety issues
This article was originally published in Scrip
Executive Summary
A clinical study testing Pfizer's Revatio (sildenafil) for the treatment of pulmonary hypertension in adults with sickle cell disease has been shut down by the National Heart, Lung, and Blood Institute (NHLBI) over safety concerns.